{"id":"W3167387657","doi":"10.1200/jco.2021.39.15_suppl.11522","title":"A phase II, open-label, randomized trial of durvalumab (D) with olaparib (O) or cediranib (C) in patients (pts) with leiomyosarcoma (LMS).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Urology; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Hazard ratio; Immunohistochemistry; Oncology; Gastroenterology; Randomized controlled trial; Progressive disease; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001335007,0.001718957,0.001911833,0.0003550389,0.0003275528,0.001183174,0.0009257937,0.001227457,0.006715803],"category_scores_gemma":[0.001320425,0.0006733256,0.0009894605,0.0003543748,0.001033421,0.001084177,0.0004417036,0.002838435,0.001424595],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008888274,"about_ca_system_score_gemma":0.001054086,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009418309,"about_ca_topic_score_gemma":0.002862042,"domain_scores_codex":[0.9995565,0.0002337027,0.00001898268,0.00008690923,0.00002954525,0.00007440124],"domain_scores_gemma":[0.999293,0.0001341979,0.0001449192,0.0000623982,0.00003535623,0.0003300336],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9644821,0.01243611,0.0008797043,0.0003451033,0.0004829711,0.00005550832,0.00005622517,0.0003989816,0.004105558,0.0001469731,0.001328956,0.01528182],"study_design_scores_gemma":[0.93143,0.06537105,0.001351053,0.00001552165,0.0001669224,0.00004648091,0.00002625606,0.000388242,0.0002647002,0.0001529152,0.0007771989,0.000009588137],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850677,0.002941429,0.0006746374,0.0009518382,0.000576216,0.005079132,0.001795929,0.0001243748,0.002788672],"genre_scores_gemma":[0.9834894,0.002022685,0.001465341,0.001505226,0.0003769193,0.004958654,0.002039366,0.0000269519,0.004115537],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006715803,"threshold_uncertainty_score":0.0224666,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1389932266974001,"score_gpt":0.4789900451769662,"score_spread":0.3399968184795661,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}